New pill takes aim at Cancer's DNA repair: first human trial begins
NCT ID NCT05055609
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called TRE-515 in adults with advanced solid tumors that no longer respond to standard treatments. The drug works by blocking a protein cancer cells need to make DNA, potentially slowing their growth. The main goals are to check safety, find the best dose, and get a first look at whether the drug can control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRE-515 (an oral drug that targets a protein involved in DNA replication in cancer cells)
What this could lead to
If successful, this could lead to a new oral treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) study with only 94 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects that limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolina BioOncology Institute
RECRUITINGHuntersville, North Carolina, 28078, United States
Contact
Contact Phone: •••-•••-••••
-
UCLA
RECRUITINGSanta Monica, California, 90404, United States
Contact Phone: •••-•••-••••
Contact